Welcome to the Pfizer EU Policy Website.

The European regulatory system has helped extend and improve the lives of millions of European citizens and beyond through provision of safe and effective medicines. Since its formation in 1995 the European Medicines Agency (EMA) has recommended the authorisation of over 1,400 medicines. However, in order to keep pace with pharmaceutical breakthroughs as well as remain competitive and respond to global health challenges, it is vital for Europe’s regulatory system to continue to evolve.

Data and digital technology have the potential to improve access to innovative medicines and to contribute to a healthier future for European patients.

Climate change and environmental degradation pose urgent global threats and the biopharmaceutical industry has a role to play by both understanding and improving the interface between people, health and the environment.¹ Pfizer recognizes the profound societal and public health impacts that are expected to result from environmental issues.

Since the 1990s, the pharmaceutical industry has brought over 1,100 new medicines to patients in Europe.¹ However, major variations in health outcomes remain evident across Europe. For instance, people born today in Sweden can expect to live in good health about 20 years longer than people in Latvia.² Among the contributing factors to this discrepancy is the wide variation in access to innovative medicines.

The debate around supply chains for medicines has drastically accelerated with the Covid-19 pandemic. The European Commission’s recent initiative to establish a Structured dialogue on security of medicines supply is an important move. Patients, governments, industry and other supply chain actors all have insights, experiences to contribute.